Telix doses first patients in OPTIMAL-e prostate cancer trial
July 16, 2026 | 11:20
Telix Pharmaceuticals and St Vincent's Hospital announced the first patients have been dosed with TLX597-Tx in the OPTIMAL-e trial, targeting earlier stage prostate cancer treatment in Melbourne and Indianapolis.
Mobile Version